Mercury Acquisitions Corp. Will Combine With Franchise Cannabis Corp.
Mercury Acquisitions Corp. Will Combine With Franchise Cannabis Corp.
The resulting issuer plant to continue to ran Franchise’s business in the medical cannabis and pharmaceutical industries and be listed on the TSXV. Mercury Acquisitions Corp. (TSXV:MERC) announced Thursday its subsidiary 2868303 Ontario Inc., also known as Mercury Subco will amalgamate with Franchise Cannabis Corp. to finalize the company’s qualifying transaction in relation to the policies of the TSX Venture Exchange.
水星收購公司(TSXV：MERC)週四宣佈其子公司2868303安大略省公司，也被稱為水星分部 將與特許經營大麻公司合併，以敲定該公司的資格交易關於多倫多證券交易所創業板的政策。
Under the amalgamation agreements, the combined corporation (Amalco) will be a wholly-owned subsidiary of Mercury, which will be renamed to Franchise Global Health Inc. upon the completion of the combination. At the same time, the corporate name of Amalco will be Franchise Cannabis Corp.
根據合併協議，合併後的公司(Amalco)將是水星公司的全資子公司，水星公司將更名為特許經營全球健康公司。在完成合並之後。同時，阿馬爾科的公司名稱將是特許經營大麻公司。.
The Transaction is subject to the receipt of all necessary regulatory and shareholder approvals, including approval of the TSXV, as well as the satisfaction of conditions to closing as set out in the agreement.
交易須獲得所有必要的監管及股東批准，包括多倫多證券交易所的批准，以及是否符合協議所載的成交條件。
The resulting issuer plant to continue to ran Franchise’s business in the medical cannabis and pharmaceutical industries and be listed on the TSXV.
這個由此產生的發行人工廠將繼續經營特許經營的醫用大麻和製藥行業的業務，並在多倫多證券交易所上市。
About Franchise: Franchise is a multi-national operator in the medical cannabis and pharmaceutical industries, with core operations in Germany and with operations, assets, strategic partnerships and investments internationally, including Canada, Denmark, Colombia, St. Vincent and the Grenadines, and Portugal.
關於特許經營：特許經營權是a 醫用大麻和製藥行業的跨國運營商，核心業務在德國以及與國際業務、資產、戰略伙伴關係和投資的合作，包括加拿大、丹麥、哥倫比亞、聖文森特和格林納丁斯以及葡萄牙.
The company aims to develop a fully integrated, leading European medical cannabis business, with the goal of providing high-quality pharmaceutical-grade medical cannabis to distribution partners and, ultimately, to patients, at competitive prices.
該公司旨在發展完全整合的、領先的歐洲醫用大麻業務，目標是向分銷夥伴提供高質量的藥用大麻，並最終以具有競爭力的價格向患者提供。
What’s more, Franchise has also entered into an agreement to acquire Phatebo GmbH, which is focused on wholesale pharmaceutical distribution through import and export capabilities of a wide range of pharmaceutical and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, ADHD, multiple sclerosis and anti-depressants, among others. Phatebo conducts its business of distributing pharmaceutical products within 18 countries globally, primarily in Europe, but also with sales to Asia, Latin America and North America
更重要的是，特許經營也有達成協議收購Phatebo GmbH，它的重點是藥品批發配送通過廣泛的醫藥和醫用大麻產品的進出口能力，治療各種健康適應症，包括與癌症治療、ADHD、多發性硬化症和抗抑鬱藥等相關的藥物。Phatebo從事醫藥產品分銷業務在全球18個國家內，主要銷往歐洲，但也銷往亞洲、拉丁美洲和北美
Photo: Courtesy of CRYSTALWEED cannabis on Unsplash
圖片：Unspash上的結晶器大麻提供
